Company Profile
Ulisse BioMed S.p.A. is a biotechnology company specialized in developing medical diagnostics, theranostics and therapeutics solutions. The company has 3 technology platforms, namely, Sagitta (molecular diagnostics), NanoHybrid (theranostics and diagnostics) and Aptavir (therapeutics).
Net sales are distributed geographically as follows: Italy (88.6%), America (4.6%), Europe (6.1%) and other (0.7%).
Net sales are distributed geographically as follows: Italy (88.6%), America (4.6%), Europe (6.1%) and other (0.7%).
Key Executives
| Chief Executive Officer | |
| Head of Investor Relations |
Key Figures
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 768 | 66 | 138 | 277 | 429 |
| Consumed purchases | 542 | 316 | 328 | 117 | 141 |
| Labour costs | 1,772 | 497 | 330 | 141 | 111 |
| Operating profit | -5,911 | -4,796 | -1,306 | -604 | 224 |
| Income tax | 0 | 0 | 0 | 0 | 2 |
| Net income | -5,940 | -4,796 | -1,308 | -604 | 222 |
| Net income (Group share) | -5,940 | -4,796 | -1,308 | -604 | 222 |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | Local GAAP | Local GAAP | Local GAAP | Local GAAP | Local GAAP |
Shareholder information
| Free float | |
| Other shareholders | |
| Stefano Lo Priore | |
| Alberto Amati | |
| Algebris Investments Limited | |
| Good Harvest Ventures | |
| Locorian s.s. | |
| Copernico Innovazione S.r.l. | |
| Bantess s.s. | |
| Bruna Marini | |
| Matteo Petti |
Address
Ulisse BioMed S.p.A.
Via Aquileia 17
IT-33100 Udine
Italy
Phone number: +39 040 3757540
https://ulissebiomed.com
Contact
Please contact MyQuestion.Italy@euronext.com for Company Profile support.